Decentralized trials: what the hype gets wrong, and what it means for CRAs

Decentralized clinical trials, DCTs, are the future the industry has been promising for a decade: remote visits, home nursing, wearable data, less travel for everyone. The reality, measured against the registry, is more modest and more interesting than the conference decks admit. Here is what the data actually shows, and what it means if you monitor trials.

The adoption is real but early

A 2026 analysis in PLOS Digital Health catalogued 1,370 US-registered decentralized trials from 2000 through 2023. The count grew from 46 in 2017 to about 250 in 2023, a real climb, with the pandemic driving the 2020 jump. But two numbers puncture the hype. First, 74 percent of those trials were evaluating decentralization, testing whether a remote method works, rather than simply using it as routine practice. The field is still proving the methods, not running on them. Second, only about 3 percent were drug trials; nearly half were behavioral interventions. Decentralized methods have taken hold in digital-health and behavioral studies far more than in the pivotal pharma trials that employ most CRAs.

And the artificial intelligence everyone attaches to DCT? Fewer than 2 percent of these trials used AI tools at all. The gap between the narrative and the registry is wide.

What it does to the monitoring role

The honest read for CRAs is that decentralization reshapes the job rather than eliminating it. As remote and centralized methods spread, the CRA role shifts toward remote monitoring, supporting patients and devices, and handling digital endpoints, and away from pure on-site source verification. Industry leaders describe the post-pandemic phase as a pullback from blanket decentralization toward a "fit for purpose" approach: use the remote method where it genuinely helps, keep the site visit where it does not.

There is also a cost the vendor pitches skip. Surveys cited in the PLOS study found more than 70 percent of trial staff and participants worried about increased site burden from decentralization. The remote trial does not make the work vanish; it often moves work onto sites that lack the time, training, and budget for it. For coordinators especially, "the trial comes to the patient" can mean the extra logistics come to you.

What to make of it

If you are betting a career on where monitoring is heading, the data argues for a specific posture: the road-warrior, 100 percent source-verification model is slowly giving ground, and the skills that gain value are remote and centralized monitoring, data review, and comfort with the digital tools trials increasingly run on. But the shift is gradual, uneven, and concentrated outside big pharma trials so far. Anyone telling you the CRA travel role is about to disappear is ahead of the evidence.

What the registry cannot tell you

The registry counts decentralized trials. It cannot tell you what decentralization did to the workload of the CRAs and coordinators running them, whether the promised travel reduction materialized or the site burden just increased, or whether any of it changed pay. Those are the lived effects, and they exist only with the people who worked the trials. If decentralization has changed your job, that is exactly the evidence the data is missing. Add your datapoint to the survey.